Preclinical Oncology Services (PRECOS), the oncology-focused research and development provider, has signed a partnership agreement with Swiss non-profit organization Reliable Cancer Therapies (RCT) under which PRECOS will validate existing data on complementary cancer therapies, according to PharmaTimes.
PRECOS will provide drug efficacy services to support RCT’s research on complementary medicines. RCT funds the clinical development of potential therapies and agents that fall outside the boundaries of established clinical research in oncology.
PRECOS will use in patient-relevant cancer models, including in vitro 2D and 3D assays, in vivo therapeutic evaluations and post-study analyses, to validate existing RCT data on herbal extracts and other complementary medicines and to underpin evidence-based treatment choices by patients and health care professionals.
“There is a need for reliable data on non-conventional cancer treatments,” commented RCT founder Luc Verelst. “The majority of the research conducted to date is not sufficiently scientifically or statistically rigorous to prove the benefits of these therapies.”